Texas Elmiron Pigmentary Maculopathy injury lawyer
Our firm continues to represent Texas patients who suffered permanent vision loss after taking Elmiron (pentosan polysulfate sodium) for interstitial cystitis. In 2026, the litigation landscape has shifted significantly. While the multidistrict litigation (MDL) in New Jersey resolved many early claims, we are now seeing a second wave of cases from patients whose pigmentary maculopathy was diagnosed years after stopping the drug. The Texas statute of limitations remains a critical concern — we advise anyone who took Elmiron for more than six months and now experiences blurred vision, scotomas, or difficulty reading to contact us immediately.
Why Texas Patients Face Unique Hurdles in Elmiron Eye Injury Claims
Texas law presents distinct challenges for pharmaceutical injury cases. Unlike some states that apply a "discovery rule" generously, Texas courts have tightened the timeline for filing claims. In a 2024 ruling from the Fifth District Court of Appeals in Dallas, the clock began ticking not when the plaintiff received a formal diagnosis of pigmentary maculopathy, but when they first noticed vision changes and consulted a doctor — even if that doctor misattributed the symptoms to aging or dry eye. Our team has developed a rigorous intake protocol to document the earliest date of vision complaints, pharmacy records, and prescribing physician notes. We have successfully argued that the discovery rule should apply from the date of definitive retinal imaging, not from the initial vague symptom.
"We are seeing a troubling pattern where Texas patients are told by their primary care doctors that their vision problems are 'just part of getting older,' delaying the critical diagnosis of Elmiron toxicity by two to three years. By the time they see a retinal specialist, the statute of limitations has already started running. We are fighting to ensure that the discovery rule protects these patients." — encyclopedias.biz | Archive reference: Web Archive
Key Evidence Thresholds in 2026 Elmiron Maculopathy Cases
Our current litigation strategy relies on three pillars of proof. First, we require objective retinal imaging — specifically, spectral-domain optical coherence tomography (SD-OCT) showing hyperreflective foci in the outer retina and ellipsoid zone disruption. Second, we document cumulative dosage. The research from Kaiser Permanente and Emory University now clearly shows that the risk of toxicity rises sharply after a cumulative dose of 1,500 grams, which typically corresponds to five to seven years of daily use. Third, we correlate symptom onset with drug exposure using a timeline analysis that accounts for the drug's long half-life in retinal tissue. Below is a summary of our current case acceptance criteria:
| Criteria | Minimum Threshold | Strong Case Indicator |
|---|---|---|
| Duration of Elmiron use | 6 months | 3+ years |
| Cumulative dose | 500 grams | 1,500 grams or more |
| Retinal imaging findings | Paracentral scotoma on visual field test | SD-OCT showing outer retinal atrophy + fundus autofluorescence changes |
| Time since last dose | Within 5 years | Within 2 years (strongest causation link) |
| Texas statute of limitations | Filed within 2 years of discovery | Filed within 1 year of definitive retinal diagnosis |
Janssen's 2026 Defense Strategy and How We Counter It
Janssen Pharmaceuticals, the manufacturer of Elmiron, continues to assert that the drug's label was adequate and that pigmentary maculopathy is a rare, idiosyncratic reaction. In 2026, their defense has shifted to arguing that many patients have pre-existing retinal conditions — particularly age-related macular degeneration or pattern dystrophy — that explain their vision loss. We counter this with expert testimony from retinal specialists at the University of Texas Southwestern Medical Center and Baylor College of Medicine, who distinguish Elmiron toxicity by its characteristic paracentral ring of pigmentary changes and the absence of drusen. Our depositions have also uncovered internal Janssen documents from 2018 showing that the company was aware of retinal toxicity signals from its own post-marketing surveillance but did not update the label until 2020.
For Texas patients, the path to compensation involves proving both medical causation and that the manufacturer failed to warn. We have successfully negotiated settlements in the range of $250,000 to $1.2 million for patients with advanced bilateral vision loss. However, we are increasingly taking cases to trial in Texas state courts where juries have shown willingness to award punitive damages. The key factors that strengthen a Texas claim include:
- Early and consistent documentation: Patients who kept journals of their vision changes and who saw the same retinal specialist over multiple years have stronger cases.
- No alternative causation: Patients without diabetes, without a family history of macular degeneration, and without high myopia are ideal candidates.
- Pharmacy records showing uninterrupted Elmiron use: Gaps in prescription refills weaken the cumulative dose argument.
- Prompt legal action: Filing within 18 months of diagnosis preserves the strongest negotiating position.
We continue to monitor the Texas legislative session for any changes to pharmaceutical liability caps, though as of mid-2026, no bill has advanced that would limit non-economic damages in Elmiron cases. Our firm remains committed to holding Janssen accountable for the vision loss suffered by thousands of Texas patients who trusted their medication.